Announcement, Partner Highlight, Press Release | 08.24.22 LumaBridge and the Parker Institute for Cancer Immunotherapy Form Strategic Alliance to Speed Access to Clinical Trial Services for Partners
Announcement, Our Impact, Press Release | 07.27.22 Empowering Tomorrow’s Great Minds in Cancer Research: The Parker Institute for Cancer Immunotherapy Awards up to $4.5 Million to Nine Early Career Researchers
Announcement, Partner Highlight, Press Release | 06.08.22 The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies
Announcement, Press Release | 06.03.22 Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer
Announcement, Press Release | 11.03.21 The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Dosed in First-Line Pancreatic Cancer Platform Trial
Partner Highlight, Press Release | 06.15.21 NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer
Press Release | 03.03.21 Funding the Future of Cancer Research: The Parker Institute for Cancer Immunotherapy Awards Nearly $3 Million to Six Early Career Researchers
Press Release | 02.16.21 Ute Dugan Joins the Parker Institute for Cancer Immunotherapy as Senior Vice President of Clinical Research
Announcement, Our Impact, Press Release, Research Update | 10.09.20 An Initiative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer
Announcement, Press Release | 07.23.20 The Parker Institute for Cancer Immunotherapy Appoints Immunotherapy Expert John Connolly as Chief Scientific Officer
Announcement, Press Release | 04.09.20 The Parker Institute for Cancer Immunotherapy Appoints Seasoned Health Care Leader Frederic Pla as Chief Operating Officer